Coster S, Fallowfield L J
CRC Psychosocial Oncology Group, School of Biological Sciences, University of Sussex, Falmer, East Sussex, BN1 9QG, UK.
Breast. 2002 Feb;11(1):1-12. doi: 10.1054/brst.2001.0397.
This paper reviews studies which have examined the impact of endocrine therapy on the quality of life (QOL) of patients with breast cancer. In patients with primary disease, published studies suggest that endocrine therapies, such as tamoxifen, significantly increase both gynaecological and vasomotor symptoms. However, few studies have been able to demonstrate the impact which these symptoms have on patients' QOL. This failure can be partially attributed to a range of methodological problems. Psychosocial research in advanced disease has largely consisted of randomized controlled studies with QOL as one of several study endpoints. Second generation treatments, such as aromatase inhibitors, have frequently been compared with older treatments, such as progestin therapies. Unfortunately, QOL data reported in these studies have tended to be fairly limited. Problems with existing QOL research in endocrine treatment are discussed and recommendations are made for further work.
本文综述了有关研究，这些研究探讨了内分泌治疗对乳腺癌患者生活质量（QOL）的影响。在原发性疾病患者中，已发表的研究表明，内分泌治疗，如他莫昔芬，会显著增加妇科症状和血管舒缩症状。然而，很少有研究能够证明这些症状对患者生活质量的影响。这种不足部分可归因于一系列方法学问题。晚期疾病的心理社会研究主要包括以生活质量作为几个研究终点之一的随机对照研究。第二代治疗方法，如芳香化酶抑制剂，经常与 older treatments，如孕激素疗法进行比较。不幸的是，这些研究中报告的生活质量数据往往相当有限。本文讨论了内分泌治疗中现有生活质量研究存在的问题，并对进一步的研究工作提出了建议。 （注：这里“older treatments”直译为“较旧的治疗方法”，可能结合上下文更准确的表述还需进一步明确其指代的具体药物等，但按要求不添加解释直接翻译了）
